Abstract:Consistent with its highest abundance in humans, cytochrome P450 (CYP) 3A is responsible for the metabolism of about 60% of currently known drugs. However, this unusual low substrate specificity also makes CYP3A4 susceptible to reversible or irreversible inhibition by a variety of drugs. Mechanism-based inhibition of CYP3A4 is characterised by nicotinamide adenine dinucleotide phosphate hydrogen (NADPH)-, time- and concentration-dependent enzyme inactivation, occurring when some drugs are converted by CYP isoenzymes to reactive metabolites capable of irreversibly binding covalently to CYP3A4. Approaches using in vitro , in silico and in vivo models can be used to study CYP3A4 inactivation by drugs. Human liver microsomes are always used to estimate inactivation kinetic parameters including the concentration required for half-maximal inactivation ( K I ) and the maximal rate of inactivation at saturation ( k inact ). Clinically important mechanism-based CYP3A4 inhibitors include antibacterials (e.g. clarithromycin, erythromycin and isoniazid), anticancer agents (e.g. tamoxifen and irinotecan), anti-HIV agents (e.g. ritonavir and delavirdine), anti-hypertensives (e.g. dihydralazine, verapamil and diltiazem), sex steroids and their receptor modulators (e.g. gestodene and raloxifene), and several herbal constituents (e.g. bergamottin and glabridin). Drugs inactivating CYP3A4 often possess several common moieties such as a tertiary amine function, furan ring, and acetylene function. It appears that the chemical properties of a drug critical to CYP3A4 inactivation include formation of reactive metabolites by CYP isoenzymes, preponderance of CYP inducers and P-glycoprotein (P-gp) substrate, and occurrence of clinically significant pharmacokinetic interactions with coadministered drugs. Compared with reversible inhibition of CYP3A4, mechanism-based inhibition of CYP3A4 more frequently cause pharmacokinetic-pharmacodynamic drug-drug interactions, as the inactivated CYP3A4 has to be replaced by newly synthesised CYP3A4 protein. The resultant drug interactions may lead to adverse drug effects, including some fatal events. For example, when aforementioned CYP3A4 inhibitors are coadministered with terfenadine, cisapride or astemizole (all CYP3A4 substrates), torsades de pointes (a life-threatening ventricular arrhythmia associated with QT prolongation) may occur. However, predicting drug-drug interactions involving CYP3A4 inactivation is difficult, since the clinical outcomes depend on a number of factors that are associated with drugs and patients. The apparent pharmacokinetic effect of a mechanism-based inhibitor of CYP3A4 would be a function of its K I , k inact and partition ratio and the zero-order synthesis rate of new or replacement enzyme. The inactivators for CYP3A4 can be inducers and P-gp substrates/inhibitors, confounding in vitro-in vivo extrapolation. The clinical significance of CYP3A inhibition for drug safety and efficacy warrants closer understanding of the mechanisms for each inhibitor. Furthermore, such inactivation may be exploited for therapeutic gain in certain circumstances.

Drugs As CYP3A Probes, Inducers, and Inhibitors

Investigation on Modulation of Human Cytochrome P450 and P-glycoprotein by Herb or Natural Product Using in Vivo Probe Substrate

Progress in research of cytochrome P450 3A4 gene polymorphism

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Advances in Research on Human Cytochrome P450 3A Probes

Cytochrome P450 Enzymes and Drug Metabolism in Humans

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development

[Heterogeneous expression of human CYP and its application in early stage of new drug research and development].

Functional interactions between P-glycoprotein and CYP3A in drug metabolism

Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

Genomic and Proteomic Approaches to Identify Mechanism of Regulation of Cytochrome P450 3a Enzymes

CYP450 Induction Based Drug-Drug Interaction and Evaluation Methodology

Non-cytochrome P450 Enzymes Involved in the Oxidative Metabolism of Xenobiotics: Focus on the Regulation of Gene Expression and Enzyme Activity.

Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

Cytochrome P450 2C8 and Drug Metabolism.

Fluorescent probes for the detection and imaging of Cytochrome P450

Insights into CYP2B6-mediated drug-drug interactions